Want to see PHAT full AI Analyst Report?
PHAT Stock Chart & Stats
$8.77
$0.51(4.46%)
At close: 4:00 PM EDT
$8.77
$0.51(4.46%)
Day’s Range― - ―
52-Week Range$6.82 - $18.31
Previous Close$11.95
Volume664.73K
Average Volume (3M)1.17M
Market Cap
$559.83M
Enterprise Value$1.28B
Total Cash (Recent Filing)$182.48M
Total Debt (Recent Filing)$167.11M
Price to Earnings (P/E)―
Beta2.03
Next Earnings
Nov 05, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.28
Shares Outstanding80,900,930
10 Day Avg. Volume1,266,566
30 Day Avg. Volume1,167,321
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)-2.76
Price to Sales (P/S)6.91
P/FCF Ratio-7.25
Enterprise Value/Market Cap2.28
Enterprise Value/Revenue5.33
Enterprise Value/Gross Profit6.43
Enterprise Value/Ebitda-36.38
Forecast
1Y Price Target
$19.29Price Target Upside119.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$316.56M
Bulls Say, Bears Say
Bulls Say
Rapid VOQUEZNA Commercial GrowthVOQUEZNA demand is scaling rapidly, with Q2 revenue up 88% year over year and covered prescription volume up 79%. This broadening utilization supports a stronger commercial base for the franchise, although continued execution on access and distribution remains important.
Improving Operating LeverageThe company paired strong commercial growth with sharply lower cash operating expenses and its first positive operating profit excluding stock compensation. That combination indicates improving operating leverage and could help convert VOQUEZNA sales into more sustainable profitability.
Liquidity And Lower Debt Support ExecutionPositive quarterly operating cash flow, substantial cash reserves, and sharply reduced debt provide resources to fund commercialization and clinical programs. Management expects existing cash plus future operations to cover obligations without new capital raises, supporting near-term execution.
Bears Say
Persistent Losses And Negative EquityPhathom remains far from durable GAAP profitability, with large operating and net losses still translating into negative equity. This weak capital base limits financial flexibility and leaves the company more exposed if commercial progress or the path to profitability takes longer than expected.
Payer Friction And High Gross-to-net DiscountsAccess friction can slow adoption even when prescriptions are clinically appropriate, while a 55%–59% gross-to-net discount materially reduces sales realized from each prescription. Persistent payer and workflow barriers could constrain revenue conversion and profitability as the franchise expands.
Competitive Pressure From TegoprazanTegoprazan introduces a credible competitive consideration within the PCAB category and may affect how physicians view VOQUEZNA’s treatment profile. Over time, that could pressure prescribing momentum, market dynamics, or gross-to-net economics despite expected category expansion.
Phathom Pharmaceuticals News
PHAT FAQ
What was Phathom Pharmaceuticals’s price range in the past 12 months?
Phathom Pharmaceuticals lowest stock price was $6.82 and its highest was $18.31 in the past 12 months.
What is Phathom Pharmaceuticals’s market cap?
Phathom Pharmaceuticals’s market cap is $559.83M.
When is Phathom Pharmaceuticals’s upcoming earnings report date?
Phathom Pharmaceuticals’s upcoming earnings report date is Nov 05, 2026 which is in 30 days.
How were Phathom Pharmaceuticals’s earnings last quarter?
Phathom Pharmaceuticals released its earnings results on Jul 30, 2026. The company reported -$0.21 earnings per share for the quarter, missing the consensus estimate of -$0.176 by -$0.034.
Is Phathom Pharmaceuticals overvalued?
According to Wall Street analysts Phathom Pharmaceuticals’s price is currently Undervalued.
Does Phathom Pharmaceuticals pay dividends?
Phathom Pharmaceuticals does not currently pay dividends.
What is Phathom Pharmaceuticals’s EPS estimate?
Phathom Pharmaceuticals’s EPS estimate is -0.11.
How many shares outstanding does Phathom Pharmaceuticals have?
Phathom Pharmaceuticals has 80,900,930 shares outstanding.
What happened to Phathom Pharmaceuticals’s price movement after its last earnings report?
Phathom Pharmaceuticals reported an EPS of -$0.21 in its last earnings report, missing expectations of -$0.176. Following the earnings report the stock price went down -22.423%.
Which hedge fund is a major shareholder of Phathom Pharmaceuticals?
Currently, no hedge funds are holding shares in PHAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Phathom Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$19.29 (119.91% Upside)
$19.29 (119.91% Upside)
Blogger Sentiment
Bullish
PHAT Sentiment 80%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 528.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.45%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
30.71%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Phathom Pharmaceuticals
Phathom Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, dedicated to advancing and commercializing therapies for gastrointestinal ailments. A pivotal asset for the company is vonoprazan, a distinctive potassium-competitive acid blocker (P-CAB) designed to effectively inhibit gastric acid production, for which Phathom holds commercial rights across the United States, Europe, and Canada. This compound is currently undergoing advanced (Phase III) clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD), and also as a component of combination therapy with antibiotics to combat Helicobacter pylori (H. pylori) infection. Established in 2018, Phathom Pharmaceuticals maintains its corporate headquarters in Florham Park, New Jersey.
PHAT Company Deck
PHAT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational progress: sharply higher revenue (+88% YoY), disciplined expense reductions (-34% YoY in cash operating expenses), first-time operating profitability excluding stock comp, first positive cash from operations and healthy cash balance. Clinical programs (EoE Phase 2 enrollment complete; Phase 3 as-needed GERD to start Q4) and updated guidance support continued growth. Key near-term challenges are physician/payer workflow friction limiting broader adoption, a high gross-to-net discount (55%–59%) that may moderate realized revenue, a meaningful cash-pay portion of scripts (~36% in Q2), and planned back-half investments that will consume cash before anticipated durable cash flow positivity in 2027. Overall, the positives (revenue acceleration, profitability milestone, clinical progress, and liquidity) materially outweigh the listed near-term obstacles.View all PHAT earnings summariesPHAT Stock 12 Month Forecast
Average Price Target
$19.29
▲(119.91% Upside)
Technical Analysis
Geron
―
Arbutus Biopharma
―
Urogen Pharma
―
Taysha Gene Therapies
―
Zenas BioPharma, Inc.
―
Ownership Overview
8.89% Insiders
13.06% Mutual Funds
48.90% Other Institutional Investors
19.43% Public Companies and
Individual Investors